These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 30315418

  • 1. PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients.
    Lim CH, Ahn TR, Moon SH, Cho YS, Choi JY, Kim BT, Lee KH.
    Eur Radiol; 2019 Apr; 29(4):1903-1911. PubMed ID: 30315418
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Apr; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J.
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [Abstract] [Full Text] [Related]

  • 4. The diagnostic ability of 18F-FDG PET/CT for mediastinal lymph node staging using 18F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer.
    Lee JW, Kim EY, Kim DJ, Lee JH, Kang WJ, Lee JD, Yun M.
    Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
    [Abstract] [Full Text] [Related]

  • 5. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
    Simsek FS, Comak A, Asik M, Kuslu D, Balci TA, Ulutas H, Koroglu R, Kekilli E, Akatli A, Elmali F, Yalcin NC, Akyol H.
    Niger J Clin Pract; 2020 Jun; 23(6):842-847. PubMed ID: 32525121
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    Nakanishi K, Nakamura S, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, Ozeki N, Fukui T, Iwano S, Chen-Yoshikawa TF.
    BMC Cancer; 2021 Sep 02; 21(1):983. PubMed ID: 34474680
    [Abstract] [Full Text] [Related]

  • 8. Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events.
    Gomi D, Fukushima T, Kobayashi T, Sekiguchi N, Koizumi T, Oguchi K.
    Thorac Cancer; 2019 Apr 02; 10(4):980-987. PubMed ID: 30883012
    [Abstract] [Full Text] [Related]

  • 9. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J, Li C, Hu M, Lu J, Shi X, Xing L, Sun X, Fu Z, Yu J, Meng X.
    Medicine (Baltimore); 2015 May 02; 94(17):e678. PubMed ID: 25929896
    [Abstract] [Full Text] [Related]

  • 10. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, Ueda K, Tanaka N, Matsunaga N.
    Ann Nucl Med; 2009 Aug 02; 23(6):523-31. PubMed ID: 19444550
    [Abstract] [Full Text] [Related]

  • 11. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Wu H, Dong S, Li X, Shi L, Shao D, Zhang Q, Chen M, Cao Y, Thant M, Huang X.
    Lung Cancer; 2020 Feb 02; 140():80-86. PubMed ID: 31901595
    [Abstract] [Full Text] [Related]

  • 12. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K, Asakura K, Kazama A, Ozawa Y.
    World J Surg; 2016 Dec 02; 40(12):2976-2983. PubMed ID: 27456499
    [Abstract] [Full Text] [Related]

  • 13. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S.
    Eur J Cardiothorac Surg; 2013 Jul 02; 44(1):83-7. PubMed ID: 23233074
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, Qian Y, Li C, Yang J.
    Int J Cancer; 2013 Jan 15; 132(2):E37-47. PubMed ID: 22890912
    [Abstract] [Full Text] [Related]

  • 15. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X, Guo Y, Qian X.
    Med Sci Monit; 2020 Jun 02; 26():e922675. PubMed ID: 32483109
    [Abstract] [Full Text] [Related]

  • 16. Improving diagnostic performance of 18F-FDG-PET/CT for assessment of regional nodal involvement in non-small cell lung cancer.
    Yang DD, Mirvis E, Goldring J, Patel ARC, Wagner T.
    Clin Radiol; 2019 Oct 02; 74(10):818.e17-818.e23. PubMed ID: 31420186
    [Abstract] [Full Text] [Related]

  • 17. An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.
    Simsek FS, Arslan M, Dag Y.
    Bosn J Basic Med Sci; 2019 May 20; 19(2):195-200. PubMed ID: 30997878
    [Abstract] [Full Text] [Related]

  • 18. Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan.
    Honguero Martínez AF, García Jiménez MD, García Vicente A, López-Torres Hidalgo J, Colon MJ, van Gómez López O, Soriano Castrejón ÁM, León Atance P.
    Rev Esp Med Nucl Imagen Mol; 2016 May 20; 35(3):159-64. PubMed ID: 26514322
    [Abstract] [Full Text] [Related]

  • 19. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, Ueda K, Tanaka N, Matsunaga N.
    Ann Nucl Med; 2009 Jul 20; 23(5):427-35. PubMed ID: 19437097
    [Abstract] [Full Text] [Related]

  • 20. Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
    Ohno Y, Fujisawa Y, Sugihara N, Kishida Y, Seki S, Koyama H, Yoshikawa T.
    AJR Am J Roentgenol; 2017 Nov 20; 209(5):W253-W262. PubMed ID: 28929810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.